文献速递肾癌与肾肿瘤

侵袭性组织学变异型肾细胞癌合并下腔静脉癌栓的手术管理与肿瘤学结局

Surgical Management and Oncologic Outcomes of Renal Cell Carcinoma and Inferior Vena Caval Thrombi With Aggressive Histologic Variants.
PubMed 文献 · Urology · 2023-11-02

本研究回顾1990至2020年接受根治性肾切除术及下腔静脉癌栓取出术的患者,比较伴与不伴侵袭性组织学变异(AHV)者的手术管理、围手术期及肿瘤学结局。403例中94例(23.3%)伴AHV,AHV组更易表现为晚期疾病,但围手术期并发症未增加,总生存未观察到降低。肉瘤样分化与更差的总生存独立相关(HR=2.016,CI 1.38-2.95,P<.001)。

要点

  • 403例中94例(23.3%)伴AHV,含横纹肌样43例、肉瘤样39例、两者兼有12例。
  • AHV组更易表现为晚期疾病,但未观察到围手术期并发症增加或总生存降低。
  • 肉瘤样分化与更差的总生存独立相关(HR=2.016,CI 1.38-2.95,P<.001)。

核心结论

  • 伴AHV的肾细胞癌合并下腔静脉癌栓更易表现为转移性疾病,肉瘤样分化与更差的总生存相关。
  • 伴与不伴AHV的肿瘤切除具有相似的围手术期并发症,提示伴AHV的肾细胞癌合并下腔静脉癌栓患者可安全完成手术。

研究设计与样本

  • 回顾性分析1990至2020年接受根治性肾切除术及下腔静脉癌栓取出术的患者,共403例,其中94例(23.3%)伴AHV。
  • 采用Kaplan-Meier法进行生存分析,组间比较采用log-rank检验。
  • 采用多变量Cox比例风险回归评估AHV、年龄、癌栓水平、下腔静脉切除、转移及内科合并症对复发和总生存的影响。

主要发现

  • 94例(23.3%)伴AHV,包括横纹肌样43例(46%)、肉瘤样39例(41%)、两者兼有12例(13%)。
  • AHV组更易表现为晚期疾病,但未观察到围手术期并发症增加或总生存降低。
  • 中位(IQR)生存期:不伴AHV为16.7(4.8-47)个月,伴AHV为12.6(4-29)个月(P=.157)。
  • 肉瘤样分化与更差的总生存独立相关(HR=2.016,CI 1.38-2.95,P<.001)。
  • 单纯横纹肌样或横纹肌样合并肉瘤样分化的总生存相似(P=0.063)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To characterize the surgical management, perioperative, and cancer-specific outcomes, and the influence of aggressive histologic variants (AHV) on operative management among patients with renal cell carcinoma (RCC) and inferior vena cava (IVC) thrombus. RCC with rhabdoid and/or sarcomatoid differentiation, which we defined as AHV, portends a worse prognosis. AHV can be associated with a desmoplastic reaction which may complicate resection. METHODS: We reviewed patients undergoing radical nephrectomy and IVC thrombectomy between 1990 and 2020. Comparative statistics were employed as appropriate. Survival analysis was performed according to the Kaplan-Meier method, and intergroup analysis performed with log-rank statistics. Multivariable cox proportional hazards regression was used to assess the effect of AHV, age, thrombus level, vena cavectomy, metastases, and medical comorbidities on recurrence and overall survival (OS). RESULTS: Ninety-four of 403 (23.3%) patients had AHV, including 43 (46%) rhabdoid, 39 (41%) sarcomatoid, and 12 (13%) with both. AHV were more likely to present with advanced disease; however, increased perioperative complications or decreased OS were not observed. Median (IQR) survival was 16.7 (4.8-47) months without AHV and 12.6 (4-29) months with AHV (P = .157). Sarcomatoid differentiation was independently associated with worse OS (HR = 2.016, CI 1.38-2.95, P <.001), whereas rhabdoid alone or with sarcomatoid demonstrated similar OS (P = 0.063). CONCLUSION: RCC and IVC thrombus with AHV are more likely to present with metastatic disease, and sarcomatoid differentiation is associated with a worse OS. Resection of tumors with and without AHV have similar perioperative complications, suggesting that surgery can be safely accomplished in patients with RCC and IVC thrombus with AHV.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Lewis KC, Werneburg GT, Dewitt-Foy ME, et al. Surgical Management and Oncologic Outcomes of Renal Cell Carcinoma and Inferior Vena Caval Thrombi With Aggressive Histologic Variants. Urology. 2023. PMID: 37925024. doi:10.1016/j.urology.2023.10.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。